MORPHO is trading at $2.40, up 0.38% over 24 hours. It is near the $2.42 daily high and $0.05 above the $2.35 low, showing a modest positive daily move but not, by itself, a clear change in the broader trend.

The short-term hourly averages are clustered between $2.38 and $2.39, each showing a positive listed reading of 0.35% to 0.74%. The price is slightly above these averages, a supportive near-term signal, though their close clustering indicates limited separation among them.

The longer hourly average gives a contrasting signal: the 144-hour SMA is $2.55, and the supplied reading places price 5.88% below it. This gap tempers the short-term average signals and indicates that the current price has not reclaimed the longer moving-average level.

Momentum is mixed across time frames. The 1-hour RSI of 53 is near the midpoint and consistent with neither strong short-term overbought nor oversold conditions, while the 7-day RSI of 42 is weaker and points to softer recent momentum without indicating an extreme reading.

Price changes reinforce that conflict: MORPHO is down 8.61% over seven days and 11.99% over 14 days, but up 6.11% over 30 days. The longer-period gain is constructive, yet the sharper shorter-period losses show that recent price action has deteriorated relative to the monthly result.

Reported 24-hour volume is 16,227,234, with volume equal to 0.96% of market capitalization. Without a prior-volume comparison or other volume context, these figures do not establish whether participation is increasing or provide a reliable directional confirmation.

At $2.40, the token is about 42.4% below its $4.17 all-time high recorded on January 17, 2025. That distance provides historical context but does not establish a recovery target or imply that the prior high is likely to be revisited.

The overall rating is Hold. The slight daily rise, position above the short hourly averages, and positive 30-day change are counterbalanced by the 144-hour average overhead, negative seven- and 14-day returns, and subdued weekly RSI; the supplied evidence therefore supports neither a strong Buy nor a decisive Sell.